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KESAN CENDAWAN SUSU RIMAU (Lignosus rhinocerotis) KE ATAS 




Alergik asma merupakan satu penyakit yang dikaitkan dengan keradangan 
pada saluran udara dan pemodelan semula struktur pada paru-paru. Ubat-ubatan 
semasa diakui keberkesanannya, namun kebanyakannya adalah berasaskan steroid 
dan mempunyai kesan sampingan. Oleh itu, produk yang berasaskan bahan 
semulajadi harus diterokai untuk dijadikan sebagai satu alternatif dalam 
menguruskan asma. Sklerotium pada Lignosus rhinocerotis (Cooke) Ryvarden 
(cendawan susu rimau) telah digunakan sebagai ubat tradisional bagi merawat 
pelbagai penyakit termasuk asma. Namun begitu, kajian saintifik yang dilakukan 
untuk melihat kesan cendawan ini adalah terhad. Oleh itu, kajian ini dilakukan untuk 
menguji tahap keberkesanan ekstrak L. rhinocerotis (LRE) terhadap keradangan, 
pembentukan semula struktur dan hipergerakbalas (AHR) pada saluran pernafasan 
pada model murin asma. LRE disediakan melalui kaedah pengekstrakan air panas 
dengan menggunakan soklet selama 24 jam. Kajian ini dijalankan pada dua jenis 
model haiwan yang berbeza; model ovalbumin (OVA) dan model hama habuk rumah 
(HDM). Untuk membentuk model kronik, mencit betina Balb/C disensitasi dengan 
dua suntikan intraperitoneal pada hari 0 and 7 dan diikuti dengan sedutan OVA, 
untuk tiga hari seminggu selama 2, 6 dan 10 minggu. Setelah itu, LRE (kepekatan 
125, 250 dan 500 mg/kg) dan dexamethasone (3mg/kg) diberikan kepada mencit 
secara oral. Manakala, satu kumpulan mencit lain telah dibiarkan selama 2 minggu 




digunakan bagi melakukan analisis sitokin, serum untuk analisis immunoglobulin E 
(IgE), tisu paru-paru bagi analisis histologi dan nodus limfa bagi analisis subset sel. 
Sementara itu, analisis untuk kajian AHR dilakukan dalam model-HDM, yang 
bergerak balas terhadap kepekatan metacholin. Pada hari 0, mencit disensitasi, diikuti 
dengan intranasal HDM pada hari ke 7-11, dan LRE diberikan sejam selepas setiap 
cabaran. Pada hari ke 14, mencit dibius dan trakeotomi dilakukan. Kajian ini 
mendapati LRE (kepekatan 125, 250 and 500 mg/kg) mengurangkan penghasilan sel-
sel goblet dan penyusutan ketebalan dinding salur pernafasan (p<0.05). Manakala 
500 mg/kg LRE (p<0.05) menunjukkan kesan yang paling efektif dalam 
mengurangkan pengekspresian TGF-β1 dan activin A. Disamping itu, kajian juga 
mendapati dos LRE yang berbeza memberikan corak pengurangan berbeza terhadap 
sel keradangan di dalam cecair BAL, paras IgE dan sitokin Th2 (interleukin-4, IL-5, 
IL-13). Sebaliknya, analisis sitometri aliran telah menunjukkan bahawa LRE tidak 
mengurangkan peratusan sel T CD3+CD4+ dan CD3+CD8+ secara signifikan 
(p>0.05). Untuk kajian AHR pula, kumpulan-LRE telah mengurangkan aras 
kerintangan saluran udara pada kepekatan metacholin 8-32 mg/ml (p<0.05). Secara 
kesimpulannya, kajian ini menunjukkan bahawa LRE berpotensi untuk 
mengurangkan keradangan, pembentukan semula struktur dan AHR pada model 
asma; menjadikan ia sebagai alternatif yang berpotensi bagi pengurusan penyakit 








THE EFFECTS OF TIGER MILK MUSHROOM (Lignosus rhinocerotis) ON 





Allergic asthma is associated with chronic airway inflammation and 
progressive airway remodelling. Current medications are effective, but these drugs 
are mostly steroid-based medications and have side effects. Hence, natural products 
should be explored as an alternative for the management of asthma. The sclerotium 
of Lignosus rhinocerotis (Cooke) Ryvarden (Tiger Milk mushroom) is used 
traditionally to treat various illnesses including asthma. However, limited studies 
described the effect of this mushroom scientifically. Thus, this study was carried out 
to evaluate the effect of L. rhinocerotis extract (LRE) on airway inflammation, 
remodelling and airway hyper-responsiveness (AHR) in murine models of asthma. 
LRE was prepared by hot water extraction method using soxhlet. This study was 
conducted in two different types of animal models; Ovalbumin (OVA)-challenged 
model and house dust mite (HDM)-challenged model. To established chronic model 
of asthma, female Balb/C mice were sensitised with two intraperitoneal (i.p) 
injections on day 0 and 7 and further challenged with OVA-inhalation for three times 
per week for 2, 6 and 10 weeks. Treatments of LRE (125, 250, 500 mg/kg) and 
dexamethasone (3 mg/kg) were given orally upon after every challenged. One group 
of mice were left without any allergen challenged after week 10 until week 12. 
Bronchoalveolar lavage (BAL) fluid was collected for cytokine analysis, serum for 




for cell subsets analysis. Meanwhile, AHR study was carried out; HDM-model in 
response to methacholine (Mch) concentrations. Mice were sensitised on day 0, 
followed by daily HDM intranasal challenge on day 7-11, and treatment were given 
one hour prior to challenge. On day 14, the mice were anesthetised and tracheotomy 
was performed. The findings demonstrated LRE treatments (125, 250 and 500 
mg/kg) significantly inhibited the production of goblet cell and thickness of airway 
smooth muscle (p<0.05) throughout the prolonged OVA-challenged. Wheras, 500 
mg/kg LRE showed the most effective in reducing the expression of TGF-β1 and 
activin A in the remodelled airways. Moreover, this study showed that different 
dosages of LRE showed different patterns of suppression on inflammatory cells in 
BALF fluid, IgE level as well as Th2 cytokines throughout the weeks. In contrast, 
flow cytometry analysis revealed that LRE did not significantly reduce the 
percentages of CD3+CD4+ and CD3+CD8+ T-cells (p>0.05). For AHR study, LRE-
treated group significantly attenuated the level of airway resistance at 8-32 mg/ml 
Mch concentrations (p<0.05). In conclusion, these findings suggested that LRE could 
suppress airway inflammation, remodelling and AHR in mouse model of asthma; 
thus suggesting its therapeutic potential as an alternative for the management of 







1.1 Asthma  
Asthma presents a significant global health burden and it affects over 300 million 
people worldwide (Asthma, 2018; Harkness et al., 2015; Park and Tantisira, 2017). 
This figure was estimated to be increase to 400 million by 2025 (Asher and Ellwood, 
2014). Asthma is a disease that characterised by the episodes of respiratory 
symptoms such as wheeze, shortness of breath, chest tightness and cough that vary 
over time and in intensity, together with variable expiratory airflow limitation 
(Reddel et al., 2015).  
 
Asthma can be triggered by allergens, viruses, air pollutants, oxidants, certain 
drugs, chemicals, changes in temperature and pressure of the environment, emotional 
disturbances (panic attacks), hyperventilation and hypocapnia (laughter, crying, 
screaming), exercise, gastroesophageal reflux, food additives and endocrine factors 
(menstrual cycle, pregnancy, thyroid disease) (Fahy, 2015). Asthma mechanism 
involves  a complex network of inflammatory airway disease, usually caused by 
various inflammatory and structural cells leading to airway inflammation, airway 
obstruction, airway remodelling and AHR (Prado et al., 2014). In general, 
morphological changes (airway remodelling) in the epithelium (goblet cell 
metaplasia, hyperplasia, and increased mucin stores), submucosa (myofibroblast 
hyperplasia, subepithelial fibrosis and increased glandular cell volume), smooth 




vessels, usually occurred in individuals susceptible to exaggerated response to 
allergens (Lambrecht and Hammad, 2015). 
 
The T helper 2 (Th2) driven inflammation of the eosinophilic airways is 
responsible for up to 50 % of all cases of asthma, and is generally considered to be 
the major pathogenetic factor in this disease (Lloyd and Saglani, 2013; Shalaby and 
Martin, 2010). Asthmatic patients typically have elevated levels of Th2 cytokines in 
their bronchoalveolar lavage fluid (BALF) and bronchial mucosa (Barrett and 
Austen, 2009). It is well known that activated Th2 cells orchestrate pulmonary 
immune responses and mediate the inflammation of lung tissues, as well as AHR 
(Diamant et al., 2013; Fajt et al., 2013; Lin et al., 2013). Activated Th2 cells also 
inhibit the inflammation of asthmatic airways (Nagai, 2012). It is noteworthy that 
mice deficient in the Th1-type transcription factor T-bet develop spontaneous AHR 
and augmented airway eosinophilia (Finotto et al., 2002). The immunomodulation of 
the Th1/Th2 imbalance encountered in asthma patients is therefore considered to be a 
practical strategy for controlling asthma (Nagai, 2012). 
 
1.1.1 Prevalence of asthma 
Asthma is a major burden worldwide, for governments, healthcare providers, patients 
and careers (Vos et al., 2012) and there is considerable variation in asthma 
prevalence, morbidity and mortality (Gibson et al., 2013). Asthma remains a 
common cause of death in many countries and many asthma deaths are preventable 
(Lozano et al., 2012). Asthma has been shown to be underdiagnosed across all 





Asthma has been listed as the 14th most chronic disorder universally and it 
affects about 8.4 %, 7.7 % and 4.5 % in children, young adults and global 
populations respectively (National Health and Interview Survey, 2017). Globally, 
severe uncontrolled asthma accounted for 5-10 % of total asthma cases and 
contributes to 50% of total asthma cost (Al-Hajjaj, 2011; Dheda et al., 2015). On the 
basis of disability-adjusted life years, the asthma impact is considered similar to the 
other major chronic diseases such as Alzheimer's and diabetes (Croisant, 2014). Even 
though asthma is not seen to be a major cause of death, but the Global Burden of 
Disease study has reported a global age-standardised death rate of 8.0 per 100,000 in 
2013, which is equivalent to breast cancer (7.4) or pedestrian road injuries (8.0) 
(Naghavi et al., 2015).  
 
In the United Kingdom (UK), on average of three people will die from 
asthma every day (Levy et al., 2018). Meanwhile, in the United Stated, 2 % of 
patients with asthma were admitted to hospital in 2009 and 8.4 % were treated in 
emergency department (ED) (Akinbami et al., 2011). Meanwhile, more than 25 
million people were recorded to be affected, and seven million of these people were 
children (Sutherland et al., 2014). According to National Centre for Health Statistics 
(2016), asthma affects 6.3 million children in the US (8.6% of the population <18 
years of age) and associated with a substantial social and economic burden.  
 
Asthma patients were less likely to be working than those without asthma, 
and they were more likely to have restrictions on operation at their job, school or 
home (Sullivan et al., 2011) and when asthma severity worsens, a higher economic 




absent despite available treatments, thus leading to loss of productivity (Bahadori et 
al., 2009; Bonilla et al., 2005). About 52% of children with asthma had one or more 
exacerbations that put them at risk for adverse outcomes, including ED visits, 
hospitalizations, and missed school days (Akinbami et al., 2011). 
 
1.1.2 Asthma in Malaysia 
Asthma negatively affects patients’ quality of life (QoL) (Heethal et al., 2014) and 
requires regular visits to ED and hospital admissions. Thus, asthma remains a major 
public health concern. Hence, optimal asthma care is crucial to reduce the disease 
burden and to improve patients’ QoL  (Asthma, 2018; Pedersen, 2010). It requires an 
optimal process of care, adequate facilities and provision of evidenced-based 
management according to the guidelines. Through clinical audits, asthma care can be 
frequently evaluated against research-based standards which are the targets of 
important quality indicators. The top rated quality indicators for asthma care include 
asthma control monitoring, controlled medication use, asthma education and 
pulmonary function monitoring (To et al., 2010)  
 
The International Study of Asthma and Allergies in Childhood (ISAAC III), 
had estimated that the prevalence of asthma in Malaysia increased from 6.4% to 9.4 
% in children aged 6-7 years and from 9 % to 13 % in children aged from 13-14 
years (Yadav et al., 2014). According to the latest WHO data published in 2017, 
asthma death in Malaysia was reported to be 1258 or 0.91% of total death (World 
Health Rankings, 2017) and the prevalence of asthma among adults is approximately 





1.1.3 Aetiology of asthma 
The aetiology of asthma may be due to genetic, environment or interaction between 
the both factors and it caused burden to the patients and families in term of 
economic, causing loss of productivity and premature death (Barnes et al., 2015). 
Frequent asthma exacerbation is a risk factor associated with progression to severe 
disease and excessive decline in lung function (Bai et al., 2007). Severe exacerbation 
is recognised as an indication for evaluating the required level of interventional 
asthma management to reduce the potential risk of death (Ichinose et al., 2017; Price 
et al., 2014). In a conceptual model constructed using data from inner-city children, 
asthma severity was related to a defined allergy pathway that linked allergen 
sensitisation, allergy inflammation, pulmonary physiology and rhinitis (Liu et al., 
2016a). Asthma triggers, occurrences or elements that lead to initiation or worsening 
of asthma symptoms, have also been associated with severe asthma exacerbations in 
children (Sala et al., 2011).  
 
Stimulant such as allergens (cockroaches, mold, house dust mites in bedding, 
carpets and pet dander), irritants and viruses initiate asthma by interrupting the 
airway epithelial barrier integrity (Heijink et al., 2010; Norimoto et al., 2014; Post et 
al., 2012; Post et al., 2013). Reducing the integrity of epithelial barrier allows the 
allergens to reach the submucosa and enable more luminal allergens to be uptake by 
intraepithelial dendritic cells, and activated the Th2 response, thus will triggered 
asthma (Georas and Rezaee, 2014; Xiao et al., 2013). Moreover, respiratory 
infections, usually caused by viruses, are the commonest cause of acute episodes of 
wheeze or asthma in children of all ages, accounting for up to 90 % of attacks (Dondi 




amongst a significant number of older asthmatics due to poorly controlled asthma 
(Melani, 2013). In the elderly, asthma is superimposed on changes related to ageing, 
immune function and other diseases common in older age (Hanania et al., 2011). In 
elderly patients, there are at least two phenotypes, those with long-standing asthma 
and those with late onset asthma (Hanania et al., 2011).  
 
 
Factors that further provoke the allergic reactions or irritate the airways are 
also from the environmental factors. Tobacco smoke exposure correlates with more 
severe asthma and with disease persistence. Exposure to passive smoke is also 
common in children with asthma (Kit et al., 2016).  Environmental tobacco smoke 
(ETS) is associated with a higher incidence of upper respiratory tract infections, 
persistence of asthma, and greater severity of asthma exacerbations (Comhair et al., 
2011). Data from many studies suggest that active smoking by adults with asthma 
leads to steroid resistance and exposure to passive smoking probably has similar 
effects (Kobayashi et al., 2014). Besides that, smoking during and after 
pregnancy and delivery is also highly associated with a greater risk of asthma 
(Bousquet et al., 2007).  
 
In addition to this, psychological stress is also believed to worsen the 
symptoms, where it alters immune system thus increases the airway inflammatory 
response to allergens and irritants (Gold and Wright, 2005). Imbalance emotions 
were reported to increase the respiratory resistance, airway reactivity, shortness of 
breathing and reduced the peak of expiratory flow rate. Children and adolescents 
exposed to severe and chronic stressors such as those living in low-income urban 




2016). Studies have found that children with persistent and severe asthma have 
higher rates of anxiety and depression when compared with children with mild or 
severe asthma (Kohlboeck et al., 2013). Besides that, in particular, children with 
severe asthma are also at increased risk for behavioral problems such as attention 
problems (Blackman and Gurka, 2007). This comorbidity is important because the 
management of severe asthma requires careful attention to symptoms and the 
medical care plan (Booster et al., 2016). Hence, parents of children with severe 
asthma have been shown to exhibit significantly higher rates of depression, anxiety, 
and posttraumatic stress disorder. Caregivers’ psychological functioning may impact 
their ability to manage their children with asthma (Booster et al., 2016).  
 
1.1.4 Types of asthma 
Generally, asthma can be divided into few types; allergic (extrinsic), non-allergic 
(intrinsic), nocturnal, exercise-induced, steroid-resistant and occupational asthma 
(Paliwal, 2012). Allergic asthma is considered as the most common type of asthma, 
which usually induced by sensitisation to environmental allergens such as HDM, 
grass weed, fungal spore and animal dander (D’Amato et al., 2015). A recent study 
indicated that different types of aeroallergens (airborne substance) such as pollen or 
spores and specific sensitisation profiles are related to different clinical 
manifestations of allergic respiratory disease (rhinitis with/without asthma), different 
clinical symptoms and different level of severity (Valero et al., 2017). Initiation of 
immune response often begins with the activation and differentiation of specific Th2 
cells that triggered by allergen and IgE is produced (Del Giacco et al., 2017). While, 
non-allergic asthma (intrinsic) has a range of triggers including weather conditions, 




According to Yawn (2008), in nocturnal asthma, patients experience asthma 
when they are sleeping, while direct exposure to wood dust, chemical fumes or other 
irritants leads to occupational asthma. Meanwhile, the steroid-resistant asthma is 
caused by steroid overdose that leads to a severe asthmatic attack that unresponsive 
to medication and requires ventilation (Paliwal, 2012). Whereas, occupational 
asthma accounts for an important percentage of work-related respiratory illnesses 
(Malo et al., 2004). It has been reported that at least 9–15% cases of asthma in adults 
are due to occupational exposures (Boule et al., 2007). Isocyanates are widely used 
in various industrial and consumer products, and they are a major cause of chemical-
induced occupational asthma throughout the world (Bello et al., 2007). According to 
a review by the Global Alliance against Chronic Respiratory Disease, severe asthma 
is classified into three categories; (1) untreated severe asthma, (2) difficult-to-treat 
severe asthma and (3) treatment-resistant severe asthma (Bousquet et al., 2010). 
 
1.1.5 Symptoms of asthma  
Asthma is the most common chronic respiratory disease affecting people from 
childhood through to adulthood (Fuchs et al., 2017). It is a characterised by variable 
expiratory airflow limitation, classically presenting with episodes of wheeze, 
shortness of breath, chest tightness and/or cough (Reddel et al., 2015) and cough is 
the prominent symptom in the elderly asthmatics (Jones et al., 2011). People with 
asthma have an immune system that permanently tends to overact. This tendency 
goes mostly unnoticed until the mucous membranes that line the insides of the 
bronchi come into contact with specific triggers. The immune system cells in the 
membranes lining the bronchi are activated, the muscles surrounding the airways 
tense up, the membranes lining the airways become inflamed and swollen, and very 




membranes and the extra mucus production cause the airways to become narrower 
which can result in an asthma attack (Turner et al., 2012).  
 
Asthma symptoms are tending to be worsening at night, which is concordant 
with the cycle of endogenous cortisol levels. Asthma episodes are resulting from the 
airway narrowing that occurred through 3 main mechanisms; swelling, secretions and 
muscle constriction of the bronchi and it ranges broadly in severity and could resolve 
spontaneously or with minimal treatment, whereas others can lead to emergency 
room visits, hospitalization or death (Dougherty and Fahy, 2009). 
 
1.1.6 Pathophysiology of asthma 
Exposure to aeroallergens such as dust, smoke, animal dander and house dust mite 
(HDM) has been related with the induction of asthma cardinal features such as 
airway inflammation, airway obstruction and AHR (Hammad et al., 2009; Holgate, 
2008b). Asthma either allergic or non-allergic endotype depends on the cellular and 
molecular characterisation of the inflammatory cascade. Allergic asthma is usually 
eosinophilic, while non-allergic asthma may present with neutrophilic or 
paucigranulocytic phenotype and most of the non-allergic asthma is severe and 
steroid-resistant (Lötvall et al., 2011). Fundamental studies in-vitro and in-vivo have 
uncovered several molecular and cellular events that implicated in the development 
of asthma. These are including increasing production of immunoglobulin E (IgE) by 
B cells, imbalance paradigm of Th1/Th2, upregulation of Th2 cytokines, airway 
cellular infiltration, damage of mitochondria, increase the production of reactive 





1.1.6 (a) Eosinophilic asthma (Mild-to-moderate asthma) 
Th2-mediated eosinophilic airway inflammation is associated with varying degree of 
asthma severity, ranging from mild-to-moderate to severe uncontrolled disease 
(Pelaia et al., 2015). Analysis of sputum or bronchoscopy sampling suggested that 
eosinophilic airway inflammation is believed to play essential roles in the 
pathogenesis of asthma via the secretion of various inflammatory mediators together 
with cytotoxic eosinophils-derived granule proteins and lipid mediators in the airway 
(Amin et al., 2016). These mediators promote persistent inflammation that ultimately 
leading to the asthmatic exacerbations and declined lung functions which is generally 
observed in biopsies of asthmatic patient’s lung (Acharya and Ackerman, 2014; 
Trautmann et al., 2002). Increasing evidences established that eosinophils essentially 
contribute to airway remodelling in asthma (Nakagome and Nagata, 2011).  
 
Exposure of the airway to aeroallergens elicit a series of biological events 
involving interaction of the allergens with toll-like receptor (TLR), release of 
epithelial IL-25, IL-33, thymic stromal lymphopoietin (TSLP) which enhance the 
activation and development of dendritic cell and Th2 cells (Wilson et al., 2012). 
Activated dendritic cells recognise and present fragments of allergen peptides via 
major histocompatibility complex (MHC) II to naïve T lymphocytes (Th0) (Kallinich 
et al., 2007). The distinction of Th0 into Th1 or Th2 are depends on the cytokines 
milieu. Th2 cells literally induced the expression of GATA-3, an important 
transcription factor that enriches the development of Th2 production especially IL-4, 
IL-5, IL-9 and IL-13 (Kaiko et al., 2008). Additionally, IL-4 and IL-13 stimulate the 
production of IgE from B lymphocytes, that influence the secretion of eosinophil. 




stimulating factor (GM-CSF) and potent chemoattractant such as eotaxin (CCL11), 
eotaxin 2 (CCL24) and chemokine ligand 5/RANTES (CCL5)  (Wenzel, 2013). 
Meanwhile, IL-9, primarily secreted by Th9 (a subset of Th2 cells) stimulates the 
infiltration, maturation and degranulation of mast cell airway, whereas IL-5 enhances 
the induction of pulmonary eosinophil homing (Fulkerson and Rothenberg, 2013b). 
IL-4 functions by enhancing migration of eosinophil by activating airway vascular 
cell adhesion molecule 1 (VCAM-1).  
 
The pulmonary eosinophils secrete wide variety of inflammatory mediators, 
such as cysteinyl leukotrienes (LTC4, LTD4, LTE4) and cytotoxic agent like 
eosinophil derived neurotoxin, eosinophil peroxidases, eosinophil cationic protein 
and major basic protein (MBP), that caused airway inflammation and oxidative stress 
damage that can be seen in asthma (Hall and Agrawal, 2014; Pelaia et al., 2015). 
Nonetheless, both allergic and non-allergic asthma shows an increase in the level of 
Th2 cytokines, thus designated the crucial role of IL-4, IL-5 and IL-13 in the 
pathogenesis of asthma (Brusselle et al., 2013; Lambrecht and Hammad, 2015; 
Pelaia et al., 2015). 
 
1.1.6 (b) Neutrophilic asthma (Moderate-to-severe asthma) 
Apart from airway eosinophilia, asthma may be presented with neutrophilic 
phenotypes, which is extensively mediated by Th17, a subset of Th cells that secrete 
IL-17 (Simpson et al., 2014; Wood et al., 2012). This category of asthma is often 
expressed in severe/uncontrolled asthmatics, steroid insensitive and it may be 
triggered by allergens or non-allergenic triggers such as microbes, cigarette smoke, 




Jr, 2013; Polosa and Thomson, 2013; Vroman et al., 2015). Differentiation of 
thymocytes into Th17 cells depends on related orphan receptor gamma (RORɣt), a 
transcription factor that requires IL-1β, IL-6 and transforming growth factor (TGF-β) 
milieu for its upregulation and consequent Th17 differentiation (Vroman et al., 
2015). The heterogeneous nature of asthma pathogenesis has rendered a blanket 
approach to treatment and diagnosis of different asthma endotypes ineffective.  
 
Wenzel and co-workers reported that there is a high neutrophils number in 
the airway lavage of patients with severe asthma compared to patients with mild and 
moderate asthma (Wenzel et al., 1997). It is thought to be involved in the progression 
of more severe irreversible airway obstruction leading to sudden death (Shaw et al., 
2007). This statement was supported by the evidence of an excess neutrophils in 
airway secretions and sub-mucous glands in biopsy sample from patients with fatal 
asthma (Carroll et al., 2002). There were also evidences stated that mast cells have 
been linked to the pathophysiology of asthma and often associated with more severe 
asthmatic phenotypes (Andersson et al., 2016; Galli and Tsai, 2012). Abundant of 
mast cells are found to be localised within the bronchial smooth muscle bundles in 
severe asthma and trigger airway remodelling by secreting inflammatory mediators 
likes amphiregulin (Andersson et al., 2016; Lei et al., 2013). Therefore, if left 
untreated, asthma can lead to the airway irreversibility such as airway wall 
remodelling that correlate with the disease severity. Therefore, a proper 
understanding of asthma pathogenesis is essential for successful treatment discovery 
and repositioning. Figure 1.1 describes the cellular pathways involved in the 









Figure 1.1 Two different pathways lead to eosinophilic airway inflammation in 
asthma. In allergic asthma, dendritic cells present allergens to 
CD4+ T-cells, inducing T-helper (Th)2 cells, which produce 
interleukin (IL)-4, IL-5 and IL-13, and leading to IgE switching in B-
cells, airway eosinophilia and mucous hypersecretion. In nonallergic 
eosinophilic asthma, air pollutants, microbes and glycolipids induce 
the release of epithelium-derived cytokines, including IL-33, IL-25 
and thymic stromal lymphopoietin (TSLP), which activate innate 
lymphoid cells (ILCs) in an antigen-independent manner via their 
respective receptors (IL-17 receptor B (IL-17RB), ST2 and TSLP 
receptor (TSLPR)). Activated ILC2s produce high amounts of IL-5 
and IL-13, leading to eosinophilia, mucus hypersecretion and airway 
hyperreactivity. CRTH2: chemoattractant receptor homologous 
molecule expressed on Th2 cells; ALX/FPR2: receptor for lipoxin A4; 
FcεRI: high-affinity receptor for IgE; GATA3: GATA-binding protein 
3; PG: prostaglandin; ROR: retinoic acid receptor-related orphan 
receptor; NK: natural killer; MHC: major histocompatibility complex; 





1.1.7 Airway hyper-responsiveness (AHR)  
Clinically, asthma presents as a physiological dysfunction of the lung characterised 
by breathlessness, wheeze and a variable airflow obstruction (Bousquet et al., 2000). 
This accounts for the dramatic increase in responsiveness of the conducting airways 
known as airway hyper-responsiveness (AHR). AHR has long been considered a 
cardinal feature of asthma and its measurement has provided profound insights into 
the underlying pathophysiology of the disease and considered to be the most 
important symptom in asthma (Kudo et al., 2013). AHR increased contractility of the 
airways in response to a variety of stimuli. Direct stimuli (methacoline, histamine, 
leukotrienes and prostaglandins) act on respective receptors on bronchial smooth 
muscle cells, which in turn depolarise and contract, thereby constricting the bronchi 
(O’Byrne, 2010). In contrast, indirect stimuli act on intermediate pathways, such as 
via mediator release from inflammatory cells and the release of neuropeptides from 
sensory nerves (Joos and O'connor, 2003). 
 
In general, AHR in allergic asthma patients is most likely caused by chronic 
inflammation and airway remodelling. A correlation has been observed between the 
magnitude of AHR and the level of airway inflammation (Meurs et al., 2008). 
Eosinophils may play a role in AHR with numerous studies demonstrating a direct 
association between AHR and Th2 cell-driven eosinophilic airway inflammation. 
AHR had also been shown to be induced in a mouse model of allergic airway disease 
following blockade of transforming growth factor (TGF)-β1 with a neutralising 
antibody (Alcorn et al., 2007). This suggests a role for TGF-β1 in suppressing AHR 




is no clear or consistent association between immunological and structural features of 
asthma and the increased responsiveness of the airways. 
 
Airway remodelling may play a role in inducing or sustaining AHR. 
Structural changes that occur as a result of airway remodelling have been found to 
contribute to AHR, including a reduction of airway diameter, increased contractility 
of smooth muscle, and epithelial injury (Holgate, 2008a). However, there is evidence 
that airway remodelling could have a protective effect against AHR (Bates and 
Maksym, 2011; Grainge et al., 2011). This may be due to increased collagen 
deposition around the airways causing airway wall thickening and increased airway 
stiffness which would limit excessive airway narrowing (Meurs et al., 2008). Human 
studies have shown that asthmatic patients with airway wall thickening have reduced 
airway reactivity to methacholine (Broide, 2008). Contradictory to this, airway 
biopsies from asthma patients suggest the degree of smooth muscle thickness and the 
extent of sub-epithelial fibrosis is related to disease severity and magnitude of AHR 
(Southam et al., 2007). Although the exact relationship between airway remodelling 
and AHR is still unclear, it is most likely that airway remodelling changes play some 










1.1.8 Airway remodelling 
Airway remodelling can be well-defined as a set of changes in the composition, 
content and organisation of the cellular and molecular constituents of the airway wall 
(Bergeron and Boulet, 2006). This could constitute a normal development or repair 
process during the lung development, aging or as a transient response to airway/lung 
injury, with restoration of normal structures. However, it can also be a pathological 
process in response to chronic injury/inflammation, resulting in persistently altered 
airway structure and function. In severe asthma, the term "airway remodelling" 
denotes the structural alteration that occurs as a consequence of, chronic 
inflammation, contributing to airway obstruction.  
 
Airway remodelling refers to a compilation of structural modification 
characterised by epithelial damage and hyperplasia, deposition of extracellular 
matrix (ECM) factors below the basement membrane (making the airways less 
compliant), proliferation of airway smooth muscle, angiogenesis and excess mucus 
production contribute to the thickening of the airway wall which are associated with 
an irreversible loss in lung function that tracks from childhood to adulthood (Figure 
1.2) (Evans et al., 2009; Halwani et al., 2011; Lambrecht and Hammad, 2012; Martin 
and Verma, 2012). The structural airway changes are apparent in asthma even in 
mild disease (Wilson et al., 2013), however, the degree of remodeling often worsens 
with increasing disease severity (Bonsignore et al., 2015). In addition, the onset of 
the pathological changes occurs early, during the pre-school years (Saglani et al., 
2007). Jeffery (2001b) described that the asthmatic airway walls are generally 
thickened between 50 and 300% relative to the normal airway walls due to airway 




and sub-mucosa. This phenomenon leads to luminal narrowing. Furthermore, the 
epithelium layer of the nasal and lower airways in the asthmatic individuals appears 
to be more fragile and easily detach from the basement membrane. The consequence 
of these structural changes may cause partially reversible airway narrowing in mild 
asthma but mostly irreversible in chronic severe asthma airway together with airway 
hyperresponsiveness (AHR), mucus hypersecretion and airway oedema leading to a 
progressive decline in pulmonary function. There is growing support for a role of 
aberrant airway epithelial repair processes in response to persistent inflammatory 
response implicated in the development of pathological airways remodeling (Bai, 
2010; Ganesan and Sajjan, 2013). Despite evidence that inflammation is involved in 
airway remodelling, these two processes seem to evolve in parallel, although they do 
not always correlate well. Changes in structural cells could also influence 




1.1.8 (a) Epithelial layer damage 
It is known that chronic inflammation has functional effects that lead to systemic 
changes in asthma that recognised as the central component that leads to remodeling. 
The structural changes in cellular phenotypes at the molecular level is primarily 
initiated by alterations in the airway epithelium, lamina propria and submucosa 
leading to the thickening of all the components of the airway wall (inner, outer, and 







Furthermore, continuous injury to the epithelium lead to its fragility in acute 
asthma with extensive denudation, disruption, shedding and increased turnover of 
epithelial cells in severe/chronic asthma (Fixman et al., 2007). Epithelial cell 
hypertrophy contributes to regular differentiation of these cells into goblet cells that 
secrete mucus, resulting in goblet cell hyperplasia and mucous gland hyperplasia. 
Based on Holgate (2008b), shedding of epithelium, goblet cell hyperplasia, reduction 
of cell layer and upregulation of growth factors are the types of epithelial layer 
alteration in asthmatic airways wall. Epithelial changes are not only specific to 
asthma attack; they also can be observed in other airway diseases such as chronic 
obstructive pulmonary disease (COPD). Epithelial cells revealed a rapid repair 






























Figure 1.2 The airways in asthma undergo substantial structural remodelling. 
Histological section of a medium-sized airway from a person without 
asthma and a patient with severe asthma stained with Movat’s 
pentachrome stain. In asthma, the epithelium (Ep) shows mucus 
hyperplasia and hypersecretion (blue) and thickening of the basement 
membrane (Bm). Smooth muscle (Sm) volume is also increased in 
asthma. Bv=blood vessel. Reproduced, under an open access 
agreement, from Wadsworth and colleagues. IL-13, asthma, and 
glycosylation in airway epithelial repair. In: Chang C, ed. 
Carbohydrates—comprehensive studies on glycobiology and 














1.1.8 (b) Sub epithelial layer thickening 
Sub epithelial layer thickening happened due to high deposition of extracellular 
matrix proteins (ECMs) and considered as one of the features in airway remodelling 
of asthma (Manuyakorn et al., 2013). This type of thickening is confined to the 
lamina reticularis (reticular basement membrane-RBM). Immunohistochemistry test 
revealed that the thickened reticular layer is mostly consisted of collagen I, III, IV 
and fibronectin (Roche et al., 1989). Apart from that, production of ECMs in the 
airways are related to the fibroblasts and myofibroblasts, while the inflammatory 
cells such as eosinophil, mast cells and T cells accumulate in the submucosal layer, 
where the fibroblasts/myofibroblasts situated. The connection between the structural 
cells (eg: fibroblasts and epithelial cells), inflammatory cells and acquisition rate of 
ECMs determines the remodelling and fibrosis of the airways (Manuyakorn et al., 
2013). In response to damage happened, the epithelial cells release growth factors 
such as TGF-β that directly affect the synthesis of ECMs by myofibroblast/ fibroblast 
(Hostettler et al., 2008).  
 
1.1.8 (c) Airway smooth muscle hyperplasia and hypertrophy 
The increased thickness of airway smooth muscle (ASM) layer is one of the main 
factors contributing to remodelling and hyperreactivity in asthma. Indeed, the 
amount of ASM mass appears to be directly correlated to both duration and severity 
of asthma, as well as to AHR to methacholine (Pepe et al., 2005). In patients with 
asthma, and those subjects suffering from more severe disease, the oversized ASM 
bundle arises from an enlargement of ASM cell volume (cellular hypertrophy) and 




James et al., 2012). The increase of ASM mass, which likely occurs through altered 
myocyte growth and survival, may be a significant factor inducing dyspnoea in 
asthma due to its impact on airway narrowing (Al-Muhsen et al., 2011; Prakash, 
2013). It is plausible that decreasing excessive ASM would alleviate some of the 
symptoms exhibited by asthmatic patients.  
 
Increased airways smooth muscle mass has been recognised as the feature of 
asthma for decades. It is mediated by releasing of cysteinyl leukotriene from 
eosinophils. Smooth muscle play roles in bronchoconstriction, that triggered by 
direct and indirect stimuli which contribute symptoms, exacerbations and the 
remodelling process (Grainge et al., 2011). The increase in smooth muscle mass is 
associated with increases in growth factors including TGF-β1 and platelet-derived 
growth factor (Cohen et al., 2000). The muscle itself may also act as a secretory 
organ in asthma, promoting maladaptive growth and immunologic responses. A 
recent review of these properties highlighted IL-5, IL-13, TGF-β1, IL-1β and tumour 
necrosis factor as important mediators in this process (Doeing and Solway, 2013). In 
fatal asthma, smooth muscle layer in the airways increased more than 50%, 
compared to normal airways (James, 2005). 
 
1.1.8 (d) Angiogenesis 
Angiogenesis happened in airway remodelling where it developed new blood vessels 
below the basal lamina in the space between the muscle layer and the surrounding 
parenchyma (Al-Muhsen et al., 2011). This results in increased vascular areas in the 
airways, changed the blood flow and microvascular permeability and helped in 




contribute to the thickness of the airway walls even though it is quite difficult to 
quantify in vivo. Among the angiogenic agents responsible for the increased numbers 
of arterioles and capillaries detectable in asthmatic bronchi, vascular endothelial 
growth factor (VEGF) plays the most relevant pathogenic role (Hoshino et al., 2001). 
VEGF is overexpressed in the airways of patients with asthma, and this potent 
vascular growth factor is produced not only by endothelial cells but also by many 
inflammatory cells such as eosinophils, macrophages and mast cells (Tseliou et al., 
2012).  
 
1.1.8 (e) Goblet cell hyperplasia 
A hallmark of airway remodelling in asthma is represented by hyperplasia/metaplasia 
of mucus producing goblet cells (Fahy, 2002). These structural changes extent 
throughout all levels of asthma severity, but they are more prominent in severe 
asthma (Jenkins et al., 2003; Ordoñez et al., 2001). Hyperplastic goblet cells are 
largely responsible for mucus hypersecretion, which significantly contributes to 
airway narrowing in asthma. In particular, in asthmatic airways, mucin 5AC 
(MUC5AC) is the most abundant mucin glycoprotein produced by goblet cells 
(Rubin et al., 2014). Th2 cytokines, especially IL-13, are powerful inducers of goblet 
cell hyperplasia and mucus production (Fahy and Dickey, 2010). In this regard, it is 
noteworthy that airway goblet cell hyperplasia elicited by IL-13 is steroid resistant 
(Kanoh et al., 2011). IL-13-dependent goblet cell proliferation and mucus 
hypersecretion are mediated via overexpression of TGF-β2. Indeed, TGF-β2 levels 
correlate with mucin expression in asthmatic airways (Makinde et al., 2007). In 
addition to this, other cellular pathways are implicated in mucin production. In fact, 




receptor, which can be activated by EGF, TGF-α, amphiregulin, epiregulin and β 
cellulin (Rubin et al., 2014). Mucus hypersecretion could lead to airway obstruction, 
contributing to the morbidity and mortality of asthma (Curran and Cohn, 2010; Lai 
and Rogers, 2010). 
 
1.1.9  Asthma medications 
Allergy asthma is a chronic inflammatory airway disease and current treatment is 
mainly used to control the level of allergic inflammation and asthma symptoms. In 
asthma, adherence to treatment can be quite poor, ranging from <50% in children and 
30–70% in adults. This is not only related to unresolved symptoms and affected 
quality of life (QoL) but also exacerbation frequency and increase mortality 
(Engelkes et al., 2015). Asthma management aims at reducing symptoms and 
exacerbations, improving lung function and QoL besides lowering the long term side 
effects of therapies (Reddel et al., 2015). To achieve this goal, the controller (anti-
inflammatory agents) and reliever (symptom reliever drugs) are used. Controllers are 
taken daily for a long term to keep asthma under clinical control, while relievers are 
used on as-needed basis that act quickly to reverse the bronchoconstriction and 
symptoms relievers. For asthma treatment, the medications fall into two large 
categories; bronchodilators and anti-inflammatory agents. In spite of current 
available therapies, some of the asthma patients remain ineffectively controlled 
(Lang et al., 2013) and these drugs have presented a number of side effects and 








1.1.9 (a) Bronchodilators 
1.1.9 (a)(i) Methylxanthines (theophylline).   
Bronchodilators are important in the management of asthma as they play an essential 
role in reversing airway obstruction and provide “bronchoprotection” against 
bronchospasm due to exercise and other spasmogenic stimuli (GINA, 2018). Since 
the 1920s, methylxanthines have been used to treat asthma and pulmonary disease 
but the demand decline after the introduction of β2-agonists (Barnes, 2013). 
Methylxanthine is a bronchodilator agent that might also improve respiratory muscle 
function through increases in mucociliary clearance and actions to stimulate 
respiration (Neame et al., 2015). It could also show anti‐inflammatory and 
immunomodulatory actions that are related with apoptosis of granulocytes (Neame et 
al., 2015). These potential mechanisms had supported methylxanthine treatment for 
patients with acute asthma over decades. However, the current international 
guidelines no longer recommend methylxanthines for acute asthma treatment due to 
the narrow therapeutic concentration window that can result in adverse effects such 
as vomiting, arrhythmias, and seizure (Milan et al., 2012). 
 
1.1.9 (a)(ii) Long-acting inhaled β-Adrenergic agonists.   
Since 3000 B.C ago, the β-adrenergic agonist is one of the oldest classes of treatment 
to treat breathing problems. The active ingredient such as epinephrine was found to 
have α- and β-receptor agonist effects. β2-agonists can be classified into short-acting 
β2-agonists (SABAs) and long-acting β2-agonists (LABA). Albuterol and terbutaline 
are examples of SABA which are hydrophilic and give effects up to 4 to 6 hours, 
while LABA (eg: formoterol, salmeterol, arformoterol, formoterol and indacaterol) 
